Comparative study between uses of GnRH- agonist versus hCG as an ovulation trigger in patients with polycystic ovary syndrome in antagonist protocol
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20150447Keywords:
Polycystic ovary syndrome, Anovulatory, HyperstimulationAbstract
Background: Polycystic ovary syndrome is one of the major causes of infertility. Almost 75% of ovulatory women have PCOS. Ovarian hyperstimulation syndrome and multiple pregnancies are known complications of PCOS in ART. Many studies are available now, to reduce the incidence and severity of OHSS in these patients, at the same time achieving acceptable pregnancy rate .In our study, we used Antagonist protocol in PCOS patients and compared the results using GnRH-Agonist versus hCG as ovulation trigger.
Methods: This is double blinded comparative study between uses of GnRH- Agonist versus hCG as an ovulation trigger in 100 patients with polycystic ovary syndrome in antagonist protocol, done in private ART setting. In the study, 100 patients randomly allotted in two groups (A & B), each 50 patients, given ovulation trigger (When leading three follicles were >18 mm) as group A-GnRH-Agonist (Inj. Triptoreline 0.1 mg, 12 hours apart two doses subcutaneously) and group B hCG as (Inj. Recombinant hCG, 250 mcg single dose subcutaneously).
Results: In our study, In 50 patients of group A, total 31 patients were pregnant. In group B of 50 cases, 29 patients were pregnant. There was no significant difference between two groups (P>0.05). Incidence of ovarian hyperstimulation syndrome is significantly less in PCOS patients, when GnRH agonist is used as ovulation trigger in Antagonist protocol, as compared to hCG (P <0.01).The incidence was mild OHSS was significantly(P<0.05) less in GnRH group. There was no significant difference in incidence of moderate OHSS (P>0.05). None patient of two groups developed severe OHSS.
Conclusions: Incidence of the ovarian hyperstimulation syndrome is significantly less in patients with Polycystic Ovarian Syndrome when GnRH agonist is used as an ovulation trigger, as compared to hCG, in Antagonist protocol. In our study, there was no significant difference in pregnancy rates between two groups.
Metrics
References
Gorry A, White DM, Franks S. Infertility in Polycystic Ovary Syndrome. Endocrine. 2006;30(1):27-33 .
Hoff JD, Quigley ME, Yen SSC. Hormonal Dynamics at mid-cycle: a re-evaluation. J Clin Endocrinol Metab 1983;57:792-96
Yen SSC, Llenera G, Little B, Pearson OH. Disappearance rate of endogenous luteinisation hormone and chorionic gonadotropin in man. J Clin Endocrinol Meatab 1968;28:1763-967.
Forman R, Fries N, Testart J, Belaiseh J, Hazout A, Frydman R. Evidence of an adverse effect of elevated serum estradiol concentrations on embryo implantation. Fertil Steril 1988;49:118-22.
Simin C, Garcia Velasco JJ, Valbuena D, Peinado JA, Moreno C, Remohi J, Pellicer C. Increasing uterine receptivity by decreasing estradiol levels during the preimplantation period in high responders with follicle stimulating hormone step- down regimen, Fertil Steril.1998;70:234-39.
P. Humaidan, S. Kol, E.G. Papanikolaou. GnRH agonist for triggering of final oocyte maturation: time for a change of practice? Hum Reprod Update, 17 (2011), pp. 510–524.
Kol SL. Luteolysis induced by a gonadotropins releasing hormone agonist is the key to prevention of ovarian hyper stimulation syndrome. Fertil Steril.2004,81:1-5.
A. Lanzone, A.M. Fulghesu, P. Villa, C. Guida, M. Guido, M.C. Nicoletti et al. Gonadotropin-releasing hormone agonist versus human chorionic gonadotropin as a trigger of ovulation in polycystic ovarian disease gonadotropin hyperstimulated cycles, Fertil Steril, 62 (1994), pp.35–41.
Itskovitz-Eldor J. Kol S, Mannaerts B. Use of single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to prevent ovarian hyper stimulation syndrome ,Human reprod 2000:15(9).
Lewit N, Kol S, Manor D. Itskovitz –Eldor J. The use of GnRH analogue for induction of the preovulatory gonadotropin surge in assisted reproduction and prevention of ovarian hyper stimulation syndrome. Gynecol Endocrinol. 1995;9(suppl 4):13-17.
Dong H. Chen S, Xing F. Application of gonadotropins releasing hormone agonist for triggering ovulation in high risk gonadotropin stimulating cycle in infertile polycystic ovarian syndrome patients. Zhonghua Fu Chan Ke Za Zhi. 1999;34(2):94-96.
Tay CC. Use of gonadotropins releasing hormone agonists to trigger ovulation, Hum Fertil (camb). 2002;5(1):G 35-37.
Shalev E, Geslevich Y and Ben-Amc. Induction of preovulatory luteinizing hormone surge by gonadotropins releasing hormone agonist in patients with high risk of ovarian hyper stimulation syndrome Hu. Reprod.1994;9:417-9.
L Engmann, L Siano, D Schmidt, J Nulsen. GnRH agonist to induce oocyte maturation during IVF in patients at high risk of OHSS, Vol. 13,Issue 5,2006 page no. 639-644 Reprductive Biomedicine.
Babayof PR, Margalioth EJ, Huleihel M, Amash A, Zylber-Haran E, Gal M, et al. Serum inhibin A, VEGF and TNF alpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial. Hum Reprod. 2006;21:1260–1265.
